VRAX (Virax Biolabs Group Limited Ordinary Shares) Stock Analysis - Analyst Ratings

Virax Biolabs Group Limited Ordinary Shares (VRAX) is a publicly traded Healthcare sector company. As of May 21, 2026, VRAX trades at $0.30 with a market cap of $1.74M and a P/E ratio of 0.00. VRAX moved +2.30% today. Year to date, VRAX is -16.86%; over the trailing twelve months it is -70.87%. Its 52-week range spans $0.10 to $3.62. Rallies surfaces VRAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate VRAX?

The average price target is $0.00.

VRAX Key Metrics

Key financial metrics for VRAX
MetricValue
Price$0.30
Market Cap$1.74M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$3.62
52-Week Low$0.10
Volume263.41K
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

VRAX Analyst Consensus

VRAX analyst coverage data. Average price target: $0.00.

Latest VRAX News

Common questions about VRAX

What do analysts rate VRAX?
The average price target is $0.00.
Does Rallies show VRAX price targets?
Yes. Rallies tracks VRAX analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is VRAX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for VRAX. It does not provide personalized investment advice.
VRAX

VRAX